{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:49:31Z","timestamp":1782953371384,"version":"3.54.5"},"reference-count":266,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2022GXNSFBA035557"],"award-info":[{"award-number":["2022GXNSFBA035557"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016697","name":"Youth Innovation Technology Project of Higher School in Shandong Province","doi-asserted-by":"publisher","award":["2022KJ197"],"award-info":[{"award-number":["2022KJ197"]}],"id":[{"id":"10.13039\/100016697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023QH427"],"award-info":[{"award-number":["ZR2023QH427"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2024M751899"],"award-info":[{"award-number":["2024M751899"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202408246"],"award-info":[{"award-number":["tsqn202408246"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.yexmp.2025.105003","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T22:32:16Z","timestamp":1760653936000},"page":"105003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"144","author":[{"given":"Shuai-Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Nan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Hui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2025.105003_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101067","article-title":"The multi-faces of Angptl8 in health and disease: novel functions beyond lipoprotein lipase modulation","volume":"80","author":"Abu-Farha","year":"2020","journal-title":"Prog. Lipid Res."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb0010","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/fca-2020-0016","article-title":"Bempedoic acid: a promising novel agent for LDL-C lowering","volume":"16","author":"Agarwala","year":"2020","journal-title":"Futur. Cardiol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0020","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1007\/s12325-022-02131-3","article-title":"Is liver transplant curative in homozygous familial hypercholesterolemia? A review of nine global cases","volume":"39","author":"Al Dubayee","year":"2022","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0025","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","article-title":"Mevinolin: a highly potent competitive inhibitor of Hydroxymethylglutaryl-coenzyme a reductase and a cholesterol-lowering agent","volume":"77","author":"Alberts","year":"1980","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexmp.2025.105003_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2020.07.028","article-title":"Lomitapide for treatment of homozygous familial hypercholesterolemia: the Qu\u00e9bec experience","volume":"310","author":"Aljenedil","year":"2020","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0035","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-023-02764-y","article-title":"The effect of PCSK9 inhibitors on LDL-C target achievement in patients with homozygous familial hypercholesterolemia: a retrospective cohort analysis","volume":"41","author":"Alshahrani","year":"2024","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0040","first-page":"1178","article-title":"A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type a and B","volume":"30","author":"Alshehri","year":"2024","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","article-title":"De novo lipogenesis in health and disease","volume":"63","author":"Ameer","year":"2014","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb0050","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1194\/jlr.M700207-JLR200","article-title":"Mechanisms involved in vitamin E transport by primary enterocytes and in vivo absorption","volume":"48","author":"Anwar","year":"2007","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0055","article-title":"Tetracyclines improve experimental lymphatic Filariasis pathology by disrupting Interleukin-4 receptor-mediated Lymphangiogenesis","volume":"131","author":"Archer","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152866","article-title":"Equity in health care financing in low- and middle-income countries: a systematic review of evidence from studies using benefit and financing incidence analyses","volume":"11","author":"Asante","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0065","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/bios12121183","article-title":"The roadmap of graphene-based sensors: electrochemical methods for bioanalytical applications","volume":"12","author":"Ashraf","year":"2022","journal-title":"Biosensors"},{"key":"10.1016\/j.yexmp.2025.105003_bb0070","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"10.1016\/j.yexmp.2025.105003_bb0075","doi-asserted-by":"crossref","unstructured":"D. Atar, J. W. Jukema, B. Molemans, et al., \"New Cardiovascular Prevention Guidelines: How to Optimally Manage Dyslipidaemia and Cardiovascular Risk in 2021 in patients needing secondary prevention?,\" Atherosclerosis 319, (2021): 51\u201361, Doi: https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.12.013.","DOI":"10.1016\/j.atherosclerosis.2020.12.013"},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/ATVBAHA.107.160408","article-title":"Vascular calcifications in homozygote familial hypercholesterolemia","volume":"28","author":"Awan","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MOL.0000000000000677","article-title":"Homozygous familial hypercholesterolemia: what treatments are on the horizon?","volume":"31","author":"Bajaj","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"issue":"8","key":"10.1016\/j.yexmp.2025.105003_bb0090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the treatment of homozygous familial hypercholesterolemia","volume":"29","author":"Bajaj","year":"2022","journal-title":"J. Atheroscler. Thromb."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0095","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of Bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0100","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70039","article-title":"Safety and efficacy of Inclisiran in hyperlipidemia: an updated Meta-analysis of randomised controlled trials","volume":"8","author":"Basit","year":"2025","journal-title":"Endocrinol. Diab. Metab."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0110","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","article-title":"Ezetimibe","volume":"11","author":"Bays","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.yexmp.2025.105003_bb0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0149-2918(01)80102-8","article-title":"Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies","volume":"23","author":"Bays","year":"2001","journal-title":"Clin. Ther."},{"issue":"30","key":"10.1016\/j.yexmp.2025.105003_bb0120","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"22","author":"Bentler","year":"2023","journal-title":"Mol. Ther. Methods Clin. Develop."},{"issue":"23","key":"10.1016\/j.yexmp.2025.105003_bb0125","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMp068242","article-title":"Exploring the uses of RNAi\u2014gene knockdown and the Nobel prize","volume":"355","author":"Bernards","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2025.105003_bb0130","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","article-title":"Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications","volume":"343","author":"Bhattacharjee","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/bdcc7010010","article-title":"Artificial intelligence in pharmaceutical and healthcare research","volume":"7","author":"Bhattamisra","year":"2023","journal-title":"Big Data Cogn. Comput."},{"key":"10.1016\/j.yexmp.2025.105003_bb0140","doi-asserted-by":"crossref","unstructured":"S. Bihorel, R. Dingman, J. Mendell, et al., \"Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged <5Years With Homozygous Familial Hypercholesterolemia,\" CPT: Pharmacometrics & Systems Pharmacology 2, (2025), Doi: https:\/\/doi.org\/10.1002\/psp4.70017.","DOI":"10.1002\/psp4.70017"},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate Lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr. Atheroscler. Rep."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/liv.13308","article-title":"Hepatotoxicity of statins and other lipid-lowering agents","volume":"37","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0155","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor Lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.yexmp.2025.105003_bb0160","first-page":"1","article-title":"Lomitapide and Mipomersen\u2014inhibiting microsomal triglyceride transfer protein (MTP) and ApoB100 synthesis","volume":"21","author":"Blom","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"issue":"14","key":"10.1016\/j.yexmp.2025.105003_bb0165","doi-asserted-by":"crossref","first-page":"d3","DOI":"10.1016\/0002-9149(94)90626-2","article-title":"Comparison of properties of four inhibitors of 3-Hydroxy-3-Methylglutaryl-coenzyme a reductase","volume":"73","author":"Blum","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yexmp.2025.105003_bb0170","doi-asserted-by":"crossref","unstructured":"J. Bor\u00e9n, M.R. Taskinen and M. Adiels, \"Kinetic studies to investigate lipoprotein metabolism,\" J. Intern. Med. 271, no. 2 (2012): 166\u2013173, https:\/\/doi:https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02497.x.","DOI":"10.1111\/j.1365-2796.2011.02497.x"},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0175","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2174\/15680266113139990032","article-title":"A perspective on quantum mechanics calculations in ADMET predictions","volume":"13","author":"Bowen","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.yexmp.2025.105003_bb0185","doi-asserted-by":"crossref","unstructured":"U.C. Broedl, C. Maugeais, J.S. Millar, et al., \"Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins,\" Circ. Res. 94, no. 12 (2004): 1554\u20131561, https:\/\/doi:https:\/\/doi.org\/10.1161\/01.RES.0000130657.00222.39.","DOI":"10.1161\/01.RES.0000130657.00222.39"},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0190","first-page":"1553","article-title":"Canadian cardiovascular society position statement on familial hypercholesterolemia: update 2018","volume":"34","author":"Brunham","year":"2018","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0195","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0958-1669(92)90082-T","article-title":"Adeno-associated virus vectors","volume":"3","author":"Carter","year":"1992","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.yexmp.2025.105003_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.abb.2015.05.011","article-title":"Receptor-based virtual screening protocol for drug discovery","volume":"582","author":"Cerqueira","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"issue":"7439","key":"10.1016\/j.yexmp.2025.105003_bb0205","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/495050a","article-title":"Rewriting a genome","volume":"495","author":"Charpentier","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2025.105003_bb0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf."},{"issue":"14","key":"10.1016\/j.yexmp.2025.105003_bb0215","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.3390\/ijms22147310","article-title":"Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0220","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0225","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0230","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2459\/JCM.0000000000001132","article-title":"Risk stratification and secondary prevention post-myocardial infarction: insights from the EYESHOT post-MI study","volume":"22","author":"Colivicchi","year":"2021","journal-title":"J. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0235","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"issue":"24","key":"10.1016\/j.yexmp.2025.105003_bb0240","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/sj.gt.3301893","article-title":"Lentiviruses in gene therapy clinical research","volume":"9","author":"Connolly","year":"2002","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0245","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9860","key":"10.1016\/j.yexmp.2025.105003_bb0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial Hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.yexmp.2025.105003_bb0255","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial Hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial Hypercholesterolaemia of the European atherosclerosis society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.yexmp.2025.105003_bb0260","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European atherosclerosis society consensus statement on homozygous familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.yexmp.2025.105003_bb0265","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2174\/1568026619666190816101948","article-title":"Virtual screening techniques in drug discovery: review and recent applications","volume":"19","author":"da Silva Rocha","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0304-4165(68)90071-8","article-title":"The role of ATP citrate Lyase in the transfer of acetyl groups in rat liver","volume":"158","author":"Daikuhara","year":"1968","journal-title":"Biochimica et Biophysica Acta (BBA)-General Subjects"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07463","article-title":"QSAR, molecular docking and ADMET properties in silico studies of novel 4, 5, 6, 7-Tetrahydrobenzo [D]-Thiazol-2-Yl derivatives derived from Dimedone as potent anti-tumor agents through inhibition of C-met receptor tyrosine kinase","volume":"7","author":"Daoui","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.yexmp.2025.105003_bb0280","first-page":"1377","article-title":"Formes Homozygotes Cutan\u00e9o-Tendineuses De Xanthomatose Hypercholest\u00e9rol\u00e9mique Dans Une Observation Familiale Exemplaire\u2014Essai De Plasmaph\u00e9 R\u00e9se \u00e0 Titre De Traitement H\u00e9roique","volume":"118","author":"De Gennes","year":"1967","journal-title":"Bull. Mem. Soc. Hop. Paris"},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0285","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0022-2275(20)38410-8","article-title":"Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein","volume":"29","author":"Demant","year":"1988","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100237","article-title":"ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy","volume":"63","author":"Deng","year":"2022","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0295","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0300","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jacl.2021.10.001","article-title":"Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: implications for clinical diagnosis","volume":"15","author":"Di Costanzo","year":"2021","journal-title":"J. Clin. Lipidol."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0305","first-page":"922","article-title":"Atherosclerosis prevention: new therapeutic strategies on the horizon","volume":"22","author":"Di Fusco","year":"2021","journal-title":"G. Ital. Cardiol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0310","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOL.0000000000000290","article-title":"Regulation of lipid metabolism by angiopoietin-like proteins","volume":"27","author":"Dijk","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0315","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13836","article-title":"Evinacumab: mechanism of action, clinical, and translational science","volume":"17","author":"Dingman","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0320","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1161\/CIRCRESAHA.116.309727","article-title":"Gene editing with CRISPR\/Cas9 RNA-directed nuclease","volume":"120","author":"Doetschman","year":"2017","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0325","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","article-title":"SREBP transcription factors: master regulators of lipid homeostasis","volume":"86","author":"Eberl\u00e9","year":"2004","journal-title":"Biochimie"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0330","first-page":"484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Series B"},{"key":"10.1016\/j.yexmp.2025.105003_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-7075-8-23","article-title":"Familial hypercholesterolemia: the lipids or the genes?","volume":"8","author":"Fahed","year":"2011","journal-title":"Nutr. Metab."},{"issue":"22","key":"10.1016\/j.yexmp.2025.105003_bb0340","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.3390\/ijms20225702","article-title":"rAAV engineering for capsid-protein enzyme insertions and mosaicism reveals resilience to mutational, structural and thermal perturbations","volume":"20","author":"Feiner","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2025.105003_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2019.101006","article-title":"ATP-citrate Lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review","volume":"77","author":"Feng","year":"2020","journal-title":"Prog. Lipid Res."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0350","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","article-title":"Safety and efficacy of Bempedoic acid: a systematic review and Meta-analysis of randomised controlled trials","volume":"22","author":"Filippo","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.yexmp.2025.105003_bb0355","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2217\/clp.13.79","article-title":"Treatment of homozygous familial hypercholesterolemia","volume":"9","author":"France","year":"2014","journal-title":"Clin. Lipidol. Metab. Disord."},{"key":"10.1016\/j.yexmp.2025.105003_bb0370","first-page":"ehae325","article-title":"Evinacumab in homozygous familial Hypercholesterolaemia: long-term safety and efficacy","author":"Gaudet","year":"2024","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","article-title":"Small interfering RNA therapeutic Inclisiran: a new approach to targeting PCSK9","volume":"34","author":"German","year":"2020","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0380","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/ATVBAHA.122.318598","article-title":"Introducing personalized medicine into pediatric homozygous familial hypercholesterolemia care","volume":"42","author":"Gidding","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0385","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1172\/JCI113259","article-title":"Suppression of apolipoprotein B production during treatment of cholesteryl Ester storage disease with lovastatin. Lmplications for regulation of apolipoprotein B synthesis","volume":"80","author":"Ginsberg","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.yexmp.2025.105003_bb0390","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0395","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00041433-199706000-00002","article-title":"Recent advances in elucidating the role of the microsomal triglyceride transfer protein in apolipoprotein B lipoprotein assembly","volume":"8","author":"Gordon","year":"1997","journal-title":"Curr. Opin. Lipidol."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0400","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/1568013033483357","article-title":"ATP-citrate Lyase: a potential target for Hypolipidemic intervention","volume":"3","author":"Groot","year":"2003","journal-title":"Curr. Med. Chem. Immunol. Endoc. Metab. Agents"},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0405","doi-asserted-by":"crossref","first-page":"1b","DOI":"10.1016\/S0002-9149(98)00030-7","article-title":"Consensus statement: role of therapy with \u201cstatins\u201d in patients with hypertriglyceridemia","volume":"81","author":"Grundy","year":"1998","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0410","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1039\/C8MD00472B","article-title":"ADMET-score\u2013A comprehensive scoring function for evaluation of chemical drug-likeness","volume":"10","author":"Guan","year":"2019","journal-title":"Medchemcomm"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0415","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in Dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.yexmp.2025.105003_bb0420","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.10.013","article-title":"A randomized study investigating the safety, tolerability, and pharmacokinetics of Evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects","volume":"314","author":"Harada-Shiba","year":"2020","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0425","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1651-2227.2004.tb00723.x","article-title":"Homozygous Hypercholesterolaemia and ezetimibe: a case report","volume":"93","author":"Hendriksz","year":"2004","journal-title":"Acta Paediatr."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0430","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.114.221242","article-title":"Anti PcSK9 antibody pharmacokinetics and low density lipoprotein cholesterol pharmacodynamics Innon human Primates are antigen affinity dependent and exhibit limited sensitivity Toneonatal Fcreceptor binding enhancement","volume":"353","author":"HenneKR","year":"2015","journal-title":"J. Pharmacol. Exp. Rapeutics"},{"key":"10.1016\/j.yexmp.2025.105003_bb0435","first-page":"163","article-title":"Clinical efficacy and safety of Evolocumab for low-density lipoprotein cholesterol reduction","author":"Henry","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0440","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/molecules23102520","article-title":"Artificial Intelligence in Drug Design","volume":"23","author":"Hessler","year":"2018","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0445","doi-asserted-by":"crossref","first-page":"195","DOI":"10.35360\/njes.781","article-title":"Semantic density and gravity in lay-oriented medical knowledge communication: the case of the EPAR summary for the public","volume":"21","author":"Hill-Madsen","year":"2022","journal-title":"Nordic J. Engl. Stud."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0450","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of Evolocumab (AMG 145), a monoclonal antibody to PCSK9, in Hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ. J."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0455","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu. Rev. Genet."},{"issue":"22","key":"10.1016\/j.yexmp.2025.105003_bb0460","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","article-title":"Inclisiran durably lowers low-density lipoprotein cholesterol and Proprotein convertase Subtilisin\/Kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study","volume":"141","author":"Hovingh","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.yexmp.2025.105003_bb0465","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/TCRM.S193971","article-title":"Clinical evaluation of Evolocumab for the treatment of homozygous familial hypercholesterolemia in Chinese patients","volume":"15","author":"Huang","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0475","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/humu.21660","article-title":"Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant Hypercholesterolemic mutations with unexpected low LDL-cl levels","volume":"33","author":"Huijgen","year":"2012","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0480","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.RV17029","article-title":"Liver transplantation for homozygous familial hypercholesterolemia","volume":"26","author":"Ishigaki","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.yexmp.2025.105003_bb0485","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s40265-015-0466-y","article-title":"Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia","volume":"75","author":"Ito","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0490","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0495","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/17425247.2016.1188802","article-title":"Current status of non-viral gene therapy for CNS disorders","volume":"13","author":"Jayant","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0500","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0505","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0510","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FJC.0000000000001073","article-title":"Efficacy and safety of Evinacumab for the treatment of hypercholesterolemia: a Meta-analysis","volume":"78","author":"Jin","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0515","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","article-title":"Safety of Alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials","volume":"118","author":"Jones","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"20","key":"10.1016\/j.yexmp.2025.105003_bb0520","doi-asserted-by":"crossref","first-page":"14372","DOI":"10.1074\/jbc.M113.459602","article-title":"Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire1\u03b1\/cJun to enhance plasma ALT\/AST","volume":"288","author":"Josekutty","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0525","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/ng.75","article-title":"Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans","volume":"40","author":"Kathiresan","year":"2008","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-021-00911-w","article-title":"LDL apheresis and Lp (a) apheresis: a clinician\u2019s perspective","volume":"23","author":"Kayikcioglu","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0535","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/ph16010064","article-title":"Current treatment options in homozygous familial hypercholesterolemia","volume":"16","author":"Kayikcioglu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.yexmp.2025.105003_bb0540","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2018.01.034","article-title":"A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)","volume":"270","author":"Kayikcioglu","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0545","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacl.2019.02.001","article-title":"Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: results of a Nationwide survey (A-HIT1 registry)","volume":"13","author":"Kayikcioglu","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0550","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacl.2020.09.002","article-title":"Negative impact of COVID-19 pandemic on the lifestyle and Management of Patients with homozygous familial hypercholesterolemia","volume":"14","author":"Kayikcioglu","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.yexmp.2025.105003_bb0555","first-page":"26","article-title":"Clinical features, diagnosis and frequency of familial hypercholesterolemia","volume":"23","author":"Khachadurian","year":"1988","journal-title":"Contrib. Infus. Therapy"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0560","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14740338.2019.1602606","article-title":"Review of the long-term safety of Lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia","volume":"18","author":"Khoury","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0565","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-022-07413-0","article-title":"Efficacy and safety of Inclisiran in patients with Polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials","volume":"38","author":"Koenig","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0570","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2047487319870007","article-title":"Microsomal triglyceride transfer protein inhibitor (Lomitapide) efficacy in the treatment of patients with homozygous familial Hypercholesterolaemia","volume":"27","author":"Kolovou","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"9858","key":"10.1016\/j.yexmp.2025.105003_bb0575","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to Proprotein convertase Subtilisin\/Kexin type 9 as monotherapy in patients with Hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0580","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0585","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.3390\/biomedicines10123273","article-title":"Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab","volume":"10","author":"Krzemi\u0144ska","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0590","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexmp.2025.105003_bb0595","doi-asserted-by":"crossref","unstructured":"M. Lagarde and N. Palmer, \"The Impact of User Fees on Access to Health Services in Low- and Middle-Income Countries,\" Cochrane Database of Systematic Reviews 2011, no. 4 (1996): Cd009094, Doi: https:\/\/doi.org\/10.1002\/14651858.CD009094.","DOI":"10.1002\/14651858.CD009094"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0600","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0605","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0610","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9150(84)90133-3","article-title":"Vitamin E and lipoproteins in Hyperlipoproteinemia","volume":"53","author":"Lambert","year":"1984","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0615","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1373\/clinchem.2007.099747","article-title":"Plasma PCSK9 concentrations correlate with LDL and Total cholesterol in diabetic patients and are decreased by Fenofibrate treatment","volume":"54","author":"Lambert","year":"2008","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb0620","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/17434440.2020.1732812","article-title":"Recent advances in devices for minimally invasive aortic valve replacement","volume":"17","author":"Lamelas","year":"2020","journal-title":"Expert Rev. Med. Devices"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0625","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14779072.2015.1030395","article-title":"Evolocumab (AMG 145) for primary hypercholesterolemia","volume":"13","author":"Langslet","year":"2015","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0630","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/83799","article-title":"Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption","volume":"27","author":"Lee","year":"2001","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0635","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dme.13817","article-title":"Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials","volume":"35","author":"Leiter","year":"2018","journal-title":"Diabet. Med."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0640","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-014-0147-x","article-title":"Potential approaches to ameliorate hepatic fat accumulation seen with MTP inhibition","volume":"37","author":"Lin","year":"2014","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0645","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/svn-2019-000290","article-title":"Artificial intelligence and big data facilitated targeted drug discovery","volume":"4","author":"Liu","year":"2019","journal-title":"Stroke Vasc. Neurol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0650","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202102669","article-title":"Fine-tuning of cholesterol homeostasis controls erythroid differentiation","volume":"9","author":"Lu","year":"2022","journal-title":"Adv. Sci."},{"issue":"1\u20132","key":"10.1016\/j.yexmp.2025.105003_bb0655","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0021-9150(87)90089-X","article-title":"A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis)","volume":"68","author":"Mabuchi","year":"1987","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0660","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the Management of Dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yexmp.2025.105003_bb0665","first-page":"1461","article-title":"Artificial intelligence in drug discovery and development","author":"Mak","year":"2024","journal-title":"Drug Discov. Eval."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0670","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1526-0968.2003.00073.x","article-title":"Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"7","author":"Makino","year":"2003","journal-title":"Ther. Apher. Dial."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0675","first-page":"28","article-title":"Alirocumab (Praluent): first in the new class of PCSK9 inhibitors","volume":"41","author":"Manniello","year":"2016","journal-title":"Pharm. Therap."},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0680","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jclinpath-2018-205221","article-title":"Contrasting effects of sterols on metabolism","volume":"71","author":"Marais","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0685","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0022-2275(20)37137-6","article-title":"Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia","volume":"38","author":"Marais","year":"1997","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0690","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","article-title":"Statins in homozygous familial hypercholesterolemia","volume":"4","author":"Marais","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0695","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/21678707.2020.1784721","article-title":"Homozygous familial hypercholesterolemia and its treatment by Inclisiran","volume":"8","author":"Marais","year":"2020","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.yexmp.2025.105003_bb0700","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-015-0460-4","article-title":"Evolocumab: First Global Approval","volume":"75","author":"Markham","year":"2015","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.yexmp.2025.105003_bb0705","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-015-0469-8","article-title":"Alirocumab: First Global Approval","volume":"75","author":"Markham","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0710","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2016.05.042","article-title":"Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia","volume":"118","author":"Martinez","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb0715","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of Paediatric patients with homozygous familial Hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.yexmp.2025.105003_bb0720","doi-asserted-by":"crossref","unstructured":"M. Matsuda, H. Yasumo, M. Okazaki, et al., \"Angiopoietin-like Protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase,\" Arterioscler. Thromb. Vasc. Biol. 27, no. 2 (2006): 366\u2013372, https:\/\/doi:https:\/\/doi.org\/10.1161\/01.ATV.0000252827.51626.89.","DOI":"10.1161\/01.ATV.0000252827.51626.89"},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0725","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice","volume":"44","author":"Maxwell","year":"2003","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0730","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbrc.2007.07.029","article-title":"Plasma PCSK9 levels correlate with cholesterol in men but not in women","volume":"361","author":"Mayne","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexmp.2025.105003_bb0735","doi-asserted-by":"crossref","unstructured":"H. Minekura, T. Kohama, H. Furukawa, et al., \"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase,\" J. Biol. Chem. 277, no. 37 (2002): 33742\u201333748, https:\/\/doi:https:\/\/doi.org\/10.1074\/jbc.M203215200.","DOI":"10.1074\/jbc.M203215200"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0740","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/hrt.2008.162909","article-title":"Controversies in familial Hypercholesterolaemia: recommendations of the NICE guideline development Group for the Identification and Management of familial Hypercholesterolaemia","volume":"95","author":"Minhas","year":"2009","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0745","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and Familial combined Hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0750","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/pharmaceutics12111051","article-title":"Large-scale production of lentiviral vectors: current perspectives and challenges","volume":"12","author":"Molina","year":"2020","journal-title":"Pharmaceutics"},{"issue":"8856","key":"10.1016\/j.yexmp.2025.105003_bb0755","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0140-6736(93)90815-X","article-title":"Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial Hypercholesterolaemia","volume":"341","author":"Moorjani","year":"1993","journal-title":"Lancet"},{"issue":"s89","key":"10.1016\/j.yexmp.2025.105003_bb0760","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.0954-6820.1938.tb19279.x","article-title":"Xanthomata, hypercholesterolemia, angina pectoris","volume":"95","author":"M\u00fcller","year":"1938","journal-title":"Acta Med. Scand."},{"issue":"23","key":"10.1016\/j.yexmp.2025.105003_bb0765","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined Hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"49","key":"10.1016\/j.yexmp.2025.105003_bb0770","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-Acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb0775","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jacc.2021.01.008","article-title":"Inclisiran: a game changer in a changing game?","volume":"77","author":"Nambi","year":"2021","journal-title":"Am. Coll. Cardiol. Found. Washington DC"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0780","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/17512433.2021.1901579","article-title":"Bempedoic acid: a cholesterol lowering agent with a novel mechanism of action","volume":"14","author":"Nguyen","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0785","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1060028020941083","article-title":"Bempedoic acid: a new drug for an old problem","volume":"55","author":"Nguyen","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"22","key":"10.1016\/j.yexmp.2025.105003_bb0790","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0795","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41434-022-00380-z","article-title":"Improving adeno-associated viral (AAV) vector-mediated transgene expression in retinal ganglion cells: comparison of five promoters","volume":"30","author":"Nieuwenhuis","year":"2023","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0800","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40256-020-00399-w","article-title":"A review of the efficacy and tolerability of Bempedoic acid in the treatment of hypercholesterolemia","volume":"20","author":"Niman","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"15","key":"10.1016\/j.yexmp.2025.105003_bb0805","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0810","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5551\/jat.RV17050","article-title":"Homozygous familial hypercholesterolemia","volume":"28","author":"Nohara","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0815","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.amjmed.2019.01.017","article-title":"Artificial intelligence transforms the future of health care","volume":"132","author":"Noorbakhsh-Sabet","year":"2019","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-014-0414-4","article-title":"Beyond statins: new lipid lowering strategies to reduce cardiovascular risk","volume":"16","author":"Noto","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0825","first-page":"16","article-title":"Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein (a)","volume":"1","author":"Nugent","year":"2020","journal-title":"J. Clin. Cardiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s43162-024-00335-3","article-title":"A Mini-review of efficacy, safety, and influence of novel Evinacumab on familial hypercholesterolemia","volume":"36","author":"Olatunji","year":"2024","journal-title":"Egypt. J. Int. Med."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb0835","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep4.1110","article-title":"CRISPR correction of a homozygous low-density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells","volume":"1","author":"Omer","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0840","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and Meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J. Intern. Med."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-020-00884-2","article-title":"The knowns and unknowns of contemporary statin therapy for familial hypercholesterolemia","volume":"22","author":"Pang","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0850","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/clp.13.74","article-title":"Lomitapide: a novel drug for homozygous familial hypercholesterolemia","volume":"9","author":"Panno","year":"2014","journal-title":"Clin. Lipidol. Metab. Disord."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0855","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40256-013-0030-7","article-title":"Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia","volume":"13","author":"Perry","year":"2013","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0860","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/CIRCULATIONAHA.108.778886","article-title":"Prosthetic heart valves: selection of the optimal prosthesis and long-term management","volume":"119","author":"Pibarot","year":"2009","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb0865","first-page":"398","article-title":"Statins: pros and cons","volume":"150","author":"Pinal-Fernandez","year":"2018","journal-title":"Med. Cl\u00edn. (Engl. Ed.)"},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb0870","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate Lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.yexmp.2025.105003_bb0875","doi-asserted-by":"crossref","unstructured":"X. Pu, M. Sale, F. Yang, et al., \"Population Pharmacokinetics and Exposure\u2013Response Modeling for Evinacumab in Homozygous Familial Hypercholesterolemia,\" CPT: Pharmacometrics & Systems Pharmacology 10, no. 11 (2021): 1412\u20131421, Doi: https:\/\/doi.org\/10.1002\/psp4.12711.","DOI":"10.1002\/psp4.12711"},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0880","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/gt.2010.157","article-title":"Liver-specific MicroRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver","volume":"18","author":"Qiao","year":"2011","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0885","first-page":"26","article-title":"Inclisiran (Leqvio)","volume":"2","author":"R. Team","year":"2022","journal-title":"Can. J. Health Technol."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0890","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0895","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(97)00168-8","article-title":"Expanded-dose simvastatin is effective in homozygous familial Hypercholesterolaemia","volume":"135","author":"Raal","year":"1997","journal-title":"Atherosclerosis"},{"issue":"20","key":"10.1016\/j.yexmp.2025.105003_bb0900","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"9965","key":"10.1016\/j.yexmp.2025.105003_bb0905","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with Evolocumab in homozygous familial Hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.yexmp.2025.105003_bb0910","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.atherosclerosis.2016.03.009","article-title":"Phenotype diversity among patients with homozygous familial hypercholesterolemia: a cohort study","volume":"248","author":"Raal","year":"2016","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.yexmp.2025.105003_bb0915","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0920","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of Inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0930","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 doses of Inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb0935","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb0940","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ehjqcco\/qcac009","article-title":"Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study","volume":"8","author":"Ray","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb0945","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with Evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia\u2014brief report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yexmp.2025.105003_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117525","article-title":"Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: an expert consensus statement from ERKNet and ESPN","volume":"392","author":"Reijman","year":"2024","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.yexmp.2025.105003_bb0955","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(24)00073-7","article-title":"Cardiovascular outcomes in patients with homozygous familial Hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries","volume":"8","author":"Reijman","year":"2024","journal-title":"Lancet Child Adolesc. Health"},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0960","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free Proprotein convertase Subtilisin\/Kexin type 9, and Alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb0965","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2174\/138161211795428768","article-title":"New lipid modulating drugs: the role of microsomal transport protein inhibitors","volume":"17","author":"Rizzo","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb0970","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/jm970701f","article-title":"Discovery of 1-(4-Fluorophenyl)-(3 R)-[3-(4-Fluorophenyl)-(3 S)-Hydroxypropyl]-(4 S)-(4-Hydroxyphenyl)-2-Azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption","volume":"41","author":"Rosenblum","year":"1998","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.yexmp.2025.105003_bb0975","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb0980","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.yexmp.2025.105003_bb0985","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of Bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"issue":"52","key":"10.1016\/j.yexmp.2025.105003_bb0990","doi-asserted-by":"crossref","first-page":"43492","DOI":"10.1074\/jbc.M112.394023","article-title":"The M2 module of the Cys-his-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway","volume":"287","author":"Saavedra","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.yexmp.2025.105003_bb0995","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1000","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s42823-023-00655-4","article-title":"Carbon-based nanomaterials for CRISPR\/Cas delivery: a perspective on the design approach","volume":"34","author":"Safarkhani","year":"2024","journal-title":"Carbon Lett."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb1005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/gt.2012.27","article-title":"Axonal transport of adeno-associated viral vectors is serotype-dependent","volume":"20","author":"Salegio","year":"2013","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb1010","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1053\/j.gastro.2006.02.027","article-title":"Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for Sitosterolemia and Xanthomatosis","volume":"130","author":"Salen","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb1015","first-page":"254","article-title":"Familial hypercholesterolemia","volume":"53","author":"Salinas","year":"2001","journal-title":"Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion"},{"issue":"8","key":"10.1016\/j.yexmp.2025.105003_bb1020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103660","article-title":"Alirocumab in lipoprotein apheresis: a synergy for patients with high-Lp (a)","volume":"62","author":"Sbrana","year":"2023","journal-title":"Transfus. Apher. Sci."},{"issue":"8934","key":"10.1016\/j.yexmp.2025.105003_bb1030","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb1035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nchembio.1199","article-title":"Target identification and mechanism of action in chemical biology and drug discovery","volume":"9","author":"Schenone","year":"2013","journal-title":"Nat. Chem. Biol."},{"issue":"21","key":"10.1016\/j.yexmp.2025.105003_bb1040","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","article-title":"Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia","volume":"322","author":"Seed","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb1045","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory Proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"20","key":"10.1016\/j.yexmp.2025.105003_bb1050","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2025.105003_bb1055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ymeth.2023.09.010","article-title":"Exploring the artificial intelligence and machine learning models in the context of drug design difficulties and future potential for the pharmaceutical sectors","volume":"219","author":"Shiammala","year":"2023","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb1060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5114\/aoms.2020.93253","article-title":"2020 guidelines of the polish Society of Laboratory Diagnostics (PSLD) and the polish lipid association (PoLA) on laboratory diagnostics of lipid metabolism disorders","volume":"16","author":"Solnica","year":"2020","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia","volume":"12","author":"Sosnowska","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb1070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb1075","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1073\/pnas.86.11.4166","article-title":"Identification of a point mutation in growth factor repeat C of the low density lipoprotein-receptor Fene in a patient with homozygous familial hypercholesterolemia that affects ligand binding and intracellular movement of receptors","volume":"86","author":"Soutar","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb1080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell. Mol. Med."},{"issue":"8","key":"10.1016\/j.yexmp.2025.105003_bb1085","first-page":"1","article-title":"Lomitapide\u2013a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb1090","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacl.2019.05.002","article-title":"A cross-National Investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman study","volume":"13","author":"Stefanutti","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb1095","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph15111389","article-title":"Long-term efficacy and safety of Evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience","volume":"15","author":"Stefanutti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb1100","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of Evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J. Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb1105","doi-asserted-by":"crossref","first-page":"66b","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb1110","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.yexmp.2025.105003_bb1115","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.yexmp.2025.105003_bb1120","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5603\/FC.2021.0005","article-title":"Evinacumab\u2014an ANGPTL3 inhibitor; a new drug in the treatment of lipid disorders. Review on the literature and clinical studies","volume":"16","author":"Surma","year":"2021","journal-title":"Folia Cardiol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5603\/CJ.a2021.0006","article-title":"Angiopoietin-like proteins inhibitors: new horizons in the treatment of Atherogenic dyslipidemia and familial hypercholesterolemia","volume":"30","author":"Surma","year":"2023","journal-title":"Cardiol. J."},{"issue":"4","key":"10.1016\/j.yexmp.2025.105003_bb1135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10557-020-07139-x","article-title":"Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance","volume":"35","author":"Susekov","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb1140","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jacl.2016.08.006","article-title":"Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia","volume":"10","author":"Taylan","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.yexmp.2025.105003_bb1145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amjcard.2020.09.015","article-title":"Cardiovascular outcome of pediatric patients with Bi-allelic (homozygous) familial hypercholesterolemia before and after initiation of multimodal lipid lowering therapy including lipoprotein apheresis","volume":"136","author":"Taylan","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yexmp.2025.105003_bb1150","article-title":"Molecular basis of sequence-dependent differential Prenylation inhibition and statin sensitivity of G proteins","volume":"36, no. s1","author":"Tennakoon","year":"2022","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb1155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/ATVBAHA.117.310217","article-title":"Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor) implications for the efficacy of Evolocumab","volume":"38","author":"Thedrez","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00251-4","article-title":"LDL apheresis","volume":"167","author":"Thompson","year":"2003","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb1165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jacc.2020.05.033","article-title":"PCSK9 inhibitors for homozygous familial hypercholesterolemia: useful but seldom sufficient","volume":"76","author":"Thompson","year":"2020","journal-title":"Am. Coll. Cardiol. Found. Washington DC"},{"issue":"7918","key":"10.1016\/j.yexmp.2025.105003_bb1170","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the Management of Homozygous Familial Hypercholesterolaemia","volume":"305","author":"Thompson","year":"1975","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb1175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/hrt.43.6.680","article-title":"Assessment of long-term plasma exchange for familial Hypercholesterolaemia","volume":"43","author":"Thompson","year":"1980","journal-title":"Heart"},{"issue":"6510","key":"10.1016\/j.yexmp.2025.105003_bb1180","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial Hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb1185","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2017.1305354","article-title":"Alirocumab for the treatment of hypercholesterolemia","volume":"17","author":"Tomlinson","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb1190","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/17425255.2020.1749261","article-title":"Pharmacokinetics of current and emerging treatments for hypercholesterolemia","volume":"16","author":"Tomlinson","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb1195","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1080\/17425255.2021.2029402","article-title":"An evaluation of the pharmacokinetics of Inclisiran in the treatment of atherosclerotic cardiovascular disease","volume":"17","author":"Tomlinson","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb1200","article-title":"Evinacumab therapy for homozygous familial hypercholesterolemia: driving lipoprotein clearance via the road less taken","volume":"2","author":"Toth","year":"2023","journal-title":"Am. Coll. Cardiol. Found. Washington DC"},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1205","first-page":"47","article-title":"The SRE: a growth factor responsive transcriptional regulator","volume":"1","author":"Treisman","year":"1990","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb1210","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/pbi.14100","article-title":"A new and novel high-Fidelity genome editing tool for Banana using Cas-CLOVER","volume":"21","author":"Tripathi","year":"2023","journal-title":"Plant Biotechnol. J."},{"issue":"10326","key":"10.1016\/j.yexmp.2025.105003_bb1220","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial Hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1225","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/07853890.2022.2059559","article-title":"Bempedoic acid and its role in contemporary Management of Hyperlipidemia in atherosclerosis","volume":"54","author":"Tummala","year":"2022","journal-title":"Ann. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2025.105003_bb1230","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of Lomitapide in patients with homozygous familial h=hypercholesterolemia: five-year data from the Lomitapide observational worldwide evaluation registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb1240","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7861\/clinmedicine.16-5-475","article-title":"European drug market entries 2015 with new mechanisms of action","volume":"16","author":"van den Heuvel","year":"2016","journal-title":"Clin. Med."},{"issue":"3","key":"10.1016\/j.yexmp.2025.105003_bb1245","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cpt.1966","article-title":"An electronic health record text mining tool to collect real-world drug treatment outcomes: a validation study in patients with metastatic renal cell carcinoma","volume":"108","author":"van Laar","year":"2020","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"issue":"11","key":"10.1016\/j.yexmp.2025.105003_bb1250","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/clc.22343","article-title":"Is high-intensity statin therapy associated with lower statin adherence compared with low-to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology\/American Heart Association cholesterol management guidelines","volume":"37","author":"Virani","year":"2014","journal-title":"Clin. Cardiol."},{"issue":"Suppl. 2","key":"10.1016\/j.yexmp.2025.105003_bb1255","first-page":"232","article-title":"Ezetimibe effectively reduces serum plant sterols in patients with Sitosterolemia","volume":"3","author":"Von Bergmann","year":"2002","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.yexmp.2025.105003_bb1260","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a) 1","volume":"57","author":"Waldmann","year":"2016","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.yexmp.2025.105003_bb1265","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1194\/jlr.M003335","article-title":"Deficiency in hepatic ATP-citrate Lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice","volume":"51","author":"Wang","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.yexmp.2025.105003_bb1270","article-title":"Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia","volume":"5 no. 7","author":"Wang","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.yexmp.2025.105003_bb1275","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International atherosclerosis society guidance for implementing best practice in the Care of Familial Hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.yexmp.2025.105003_bb1280","doi-asserted-by":"crossref","unstructured":"G. F. Watts, S. S. Tamehri Zadeh and D. C. Chan, \"ANGPTL3 as a Therapeutic Target for Treating Homozygous Familial Hypercholesterolaemia: A Shot in the Arm for Evinacumab,\" Oxford University Press UK vol. 45 no. 27 (2024): 2435\u20132438, Doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehae321.","DOI":"10.1093\/eurheartj\/ehae321"},{"issue":"25","key":"10.1016\/j.yexmp.2025.105003_bb1285","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.113.000631","article-title":"Transcatheter aortic valve replacement for bioprosthetic aortic valve failure: the valve-in-valve procedure","volume":"127","author":"Webb","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb1290","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CRD.0000000000000522","article-title":"Evinacumab-Dgnb (Evkeeza-REGN1500), a novel lipid-lowering therapy for homozygous familial hypercholesterolemia","volume":"32","author":"White","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.yexmp.2025.105003_bb1295","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl. Res."},{"issue":"5","key":"10.1016\/j.yexmp.2025.105003_bb1300","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.yexmp.2025.105003_bb1305","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/CIRCULATIONAHA.124.073233","article-title":"Efficacy and safety of Inclisiran in adolescents with genetically confirmed homozygous familial hypercholesterolemia: results from the double-blind, placebo-controlled part of the ORION-13 randomized trial","volume":"151","author":"Wiegman","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.yexmp.2025.105003_bb1310","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/bmj.a1095","article-title":"Familial Hypercholesterolaemia: summary of NICE guidance","volume":"337","author":"Wierzbicki","year":"2008","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.yexmp.2025.105003_bb1315","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.76","article-title":"Newly identified loci that influence lipid concentrations and risk of coronary artery disease","volume":"40","author":"Willer","year":"2008","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of Inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1330","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.atherosclerosis.2005.06.039","article-title":"The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy","volume":"186","author":"Yamamoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.yexmp.2025.105003_bb1335","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery","volume":"342","author":"Yan","year":"2022","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.yexmp.2025.105003_bb1345","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.7150\/ijms.56760","article-title":"Cellular and tissue selectivity of AAV serotypes for gene delivery to chondrocytes and cartilage","volume":"18","author":"Yoon","year":"2021","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.yexmp.2025.105003_bb1360","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a Meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"issue":"36","key":"10.1016\/j.yexmp.2025.105003_bb1365","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.1002\/anie.201903618","article-title":"Triple-targeting delivery of CRISPR\/Cas9 to reduce the risk of cardiovascular diseases","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew. Chem. Int. Ed."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448002500053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448002500053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:37:16Z","timestamp":1782952636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448002500053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":266,"alternative-id":["S001448002500053X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2025.105003","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2025.105003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105003"}}